Seeking a buyer as drug goes to market

Kaltwasser, Jared
November 2010
njbiz;11/1/2010, Vol. 23 Issue 44, p3
The article reports on the plan of Savient Pharmaceuticals Inc. to move forward with the launch of its lead drug Krystexxa for the treatment of chronic gout in adults.


Related Articles

  • Boost for Savient as drug gets key code. Kaitwasser, Jared // njbiz;1/16/2012, Vol. 25 Issue 3, p3 

    The article reports that Savient Pharmaceuticals Inc. gained a billing code for its refractory chronic gout drug Krystexxa from the U.S. Centers for Medicare and Medicaid Services.

  • Krystexxa for chronic gout.  // Nurse Practitioners Prescribing Reference;Winter2010/2011, Vol. 17 Issue 4, pA.19 

    The article reports on the approval of Krystexxa, a pegloticase injection from Savient Pharmaceuticals Inc. that was made up of a PEGylated uric acid specific enzyme for the treatment of chronic gout among adult patients under refractory and conventional therapies.

  • Savient Shares Tumble on Extension Safety Data.  // Bioworld Week;11/3/2008, Vol. 16 Issue 44, p3 

    The article reports on the decrease in the shares of Savient Pharmaceuticals Inc. following the company's presentation of data on its pegloticase (Puricase) for treatment-resistant gout in the U.S. Analysts' main concerns are the safety issue of the drug and the size of its market. The company...

  • Savient sells its biologics.  // Chemical Market Reporter;3/28/2005, Vol. 267 Issue 13, p2 

    Reports that Savient Pharmaceuticals Inc. has shed its global biologics manufacturing operations to two subsidiaries of Lausanne, Switzerland-based biopharmaceutical Ferring Holding SA. Amount that will be paid by Ferring; Global rights gained by Ferring to human growth hormone and other products.

  • Savient switches strategy to cure uncertain climate. KALTWASSER, JARED // njbiz;9/26/2011, Vol. 24 Issue 39, p5 

    The article features New Jersey firm Savient Pharmaceuticals as it focuses on marketing its gout drug Krystexxa which was launched in February 2011. It recalls that its board of directors initially wanted to sell the firm upon the drug's approval by the Food and Drug Administration in September...

  • US company seeks Euro partner for gout times. Owen, Olwen Glynn // European Pharmaceutical Executive;Sep2006, p14 

    The article reports on the search of a European marketing partner for Savient Pharmaceuticals Inc.'s gout medicine. Named Puricase, this polyethylene-glycolated recombinant porcine uricase is currently in Phase III clinical trials and appears to be a unique and highly effective treatment for...

  • Savient Shares Tumble on Safety Data from Extension. Breindl, Anette // BioWorld Today;10/28/2008, Vol. 19 Issue 210, p1 

    The article reports that shares of Savient Pharmaceuticals Inc. fell 73.5 percent on October 27, 2008 after the company presented data on its pegloticase for treatment-resistant gout at the American College of Rheumatology. It was noted that analysts were skeptical about a key safety issue, its...

  • Three Biotechs Cut Staff, Pursue Divergent Paths. Powers, Marie // BioWorld Today;7/10/2012, Vol. 23 Issue 132, p1 

    The article reports on layoffs made by QLT Inc., Cardiome Pharma Corp. and Savient Pharmaceuticals Inc. in 2012. QLT has elected new board of directors and plans to use its assets to advance QLT091001, a synthetic oral retinoid. Cardiome, on the other hand, decided to preserve its funds and...

  • KRYSTEXXA.  // Monthly Prescribing Reference;Dec2010, Vol. 26 Issue 12, pA11 

    The article presents Krystexxa, a drug used for treating refractory chronic gout, from Savient Pharmaceuticals Inc. in the U.S. It is medicine containing pegloticase that should only be given to patients with chronic gout, but not to those who have glucose-6-phosphate dehydrogenase (G6PD)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics